Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice. 1976

R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin

5-Fluorouracil (5-FU) was compared to ftorafur, a fraudulent nucleoside analog which acts as a depot form of 5-FU, with respect to influence of dosage level and schedule of administration on toxicity in mice. When the drugs were administered daily and the duration of treatment was varied from a single dose to 32 daily treatments, the toxicity of 5-FU proved to be somewhat more than cumulative. On the other hand, the toxicity of ftorafur on daily treatment was less than cumulative. As a single treatment ftorafur was about half as toxic as 5-FU on an mg/kg basis. When the drugs were administered daily for 12 days the LD50 of ftorafur was about sevenfold that of 5-FU. When the drugs were administered as two treatments and the interval between the two treatments was varied from 0 to 14 days, it was found that 5-FU was considerably more toxic at an interval of 2-7 days than when two doses were administered simultaneously. Appreciable recovery of mice from the initial dose of 5-FU did not occur until sometime between 7 and 10 days. Host recovery from ftorafur toxicity was apparent by 2 days. The dose-mortality curves form both drugs were steep. The decreased toxicity with repeated treatment with ftorafur relative to 5-fu was not due to a decrease in the metabolism of ftorafur to 5-FU, which was much more extensive in mice compared to previously reported pharmacokinetic studies in other species. At equitoxic doses on a daily X 5 schedule, 5-FU and ftorafur had similar myelosuppressive activity. Ftorafur was, however, clearly less suppressive to both humoral and cell-mediated immunity than was 5-FU.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
April 1974, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
April 1978, Cancer treatment reports,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
July 1975, Cancer,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
March 1977, Antimicrobial agents and chemotherapy,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
September 1979, Analytical biochemistry,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
January 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
July 1975, Casopis lekaru ceskych,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
January 1979, Cancer chemotherapy and pharmacology,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
August 1974, British journal of cancer,
R K Johnson, and B T Garibjanian, and D P Houchens, and I Kline, and M R Gaston, and A B Syrkin, and A Goldin
May 1976, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!